English
往期目录
新闻公告
More
化学进展 2013, Vol. 25 Issue (09): 1450-1453 DOI: 10.7536/PC130408 前一篇   后一篇

• 癌症化学预防专辑 •

阿司匹林用于结直肠癌预防

Andrew T. Chan*   

  1. Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
  • 收稿日期:2013-01-20 出版日期:2013-09-25 发布日期:2013-07-31
  • 通讯作者: Andrew T. Chan E-mail:achan@partners.org
Richhtml ( 2 ) 下载PDF ( 929 ) 引用
导出 被引次数 ( 2 )

Aspirin for the Prevention of Colorectal Cancer

Andrew T. Chan*   

  1. Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
  • Received:2013-01-20 Online:2013-09-25 Published:2013-07-31
  • Contact: Andrew T. Chan E-mail:achan@partners.org

一直以来,实验室研究、流行病学调查和最近的随机对照临床试验都表明阿司匹林可以降低结直肠癌的风险。出于对潜在的副作用如胃肠道出血的考虑,此前美国预防医学工作组的专家曾经建议对于处于平均风险的普通人群不要常规使用阿司匹林来预防结直肠癌。然而,最近的高质量证据表明,阿司匹林不仅可以预防结直肠癌,对其它癌症也有预防作用。因此,值得重新考虑阿司匹林是否可常规用于癌症预防这个问题。本文总结了这些支持阿司匹林化学预防功效的有力证据,认为阿司匹林广泛的抗癌效应加上它在预防心血管疾病中的作用可能推动阿司匹林在众多患者中的长期应用。

关键词： 阿司匹林, 结直肠癌, 随机对照试验, 非阿司匹林非甾体抗炎药, 化学预防

Consistent experimental, epidemiologic, and recent randomized controlled trial evidence demonstrates that aspirin lowers the risk of colorectal cancer (CRC). Prior expert bodies have recommended against the routine use of aspirin to prevent CRC in individuals at average risk, particularly in view of potential adverse consequences, including gastrointestinal bleeding. However, such recommendations preceded more recent high quality evidence of the benefit of aspirin for the prevention of not only colorectal cancer, but other cancers as well. This review summarizes this compelling body of evidence supporting the chemopreventive efficacy of aspirin. A broad anti-cancer effect of aspirin coupled with its potential role in the prevention of cardiovascular disease may tip the balance in favor of chronic aspirin use for many patients.

Key words: aspirin, colorectal cancer, randomized controlled trials, nonaspirin nonsteroidal antiinflammatory drugs, chemoprevention

中图分类号: 

()

[1] Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Int. J. Cancer, 2011, 127: 2893—917
[2] Shapiro J A, Seeff L C, Thompson T D, Nadel M R, Klabunde C N, Vernon S W. Colorectal Cancer Test Use from the 2005 National Health Interview Survey. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008, 17: 1623—1630
[3] Chan A T, Giovannucci E L. Gastroenterology, 2010, 138: 2029—2043 e10
[4] Cole B F, Logan R F, Halabi S, Benamouzig R, Sandler R S, Grainge M J, Chaussade S, Baron J A. J. Natl. Cancer Inst., 2009, 101: 256—266
[5] Routine Aspirin or Nonsteroidal Anti-Inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U. S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 2007, 146: 361—364
[6] Rothwell P M, Wilson M, Elwin C E, Norrving B, Algra A, Warlow C P, Meade T W. The Lancet, 2010, 376: 1741—1750
[7] Rothwell P M, Fowkes F G, Belch J F, Ogawa H, Warlow C P, Meade T W. The Lancet, 2011, 377: 31—41
[8] Cook N R, Lee I M, Gaziano J M, Gordon D, Ridker P M, Manson J E, Hennekens C H, Buring J E. JAMA, 2005, 294: 47—55
[9] Sturmer T, Glynn R J, Lee I M, Manson J E, Buring J E, Hennekens C H. Ann. Intern. Med., 1998, 128: 713—720
[10] Burn J, Bishop D T, Mecklin J P, Macrae F, Moslein G, Olschwang S, Bisgaard M L, Ramesar R, Eccles D, Maher E R, Bertario L, Jarvinen H J, Lindblom A, Evans D G, Lubinski J, Morrison P J, Ho J W, Vasen H F, Side L, Thomas H J, Scott R J, Dunlop M, Barker G, Elliott F, Jass J R, Fodde R, Lynch H T, Mathers J C. N. Engl. J. Med., 2008, 359: 2567—2578
[11] Burn J, Gerdes A, Macrae F, Mecklin J, Moslein G, Olschwang S, Eccles D, Evans G, Bertario L, Bisgaard M, Dunlop M, Ho J W, Hodgson S, Lindblom A, Lubinski J, Morrison P J, Murday V, Ramesar R, Side L, Scott R J, Thomas J W, Vasen H F, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Mathers J C, Bishop D T. The Lancet, 2011, 378: 2081—2087
[12] Sostres C, Lanas A. Nature Reviews Gastroenterology & Hepatology, 2011, 8: 385—394
[13] Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133:199S—233S
[14] Final Report on the Aspirin Component of the Ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med., 1989, 321: 129—135
[15] Ridker P M, Cook N R, Lee I M, Gordon D, Gaziano J M, Manson J E, Hennekens C H, Buring J E. N. Engl. J. Med., 2005, 352: 1293—1304
[16] Chan A T, Ogino S, Fuchs C S. JAMA, 2009, 302: 649—658
[17] Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian Z R, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt J A, Giovannucci E, Fuchs C S, Chan A T, Ogino S. N. Engl. J. Med., 2012, 367: 1596—1606
[18] Aspirin for the Prevention of Cardiovascular Disease: U. S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med., 2009, 150: 396—404
[1] Michael B. Sporn, Karen T. Liby. 癌症化学预防：过去,现在和未来[J]. 化学进展, 2013, 25(09): 1421-1428.
[2] Patricia A. Egner, 王金兵, 朱源荣, Lisa P. Jacobson, Derek Ng, Alvaro Muñoz, Jed W. Fahey, 陈建国, 陈陶阳, 钱耕荪, John D. Groopman, Thomas W. Kensler*. 中国启东肝癌预防：黄曲霉毒素生物标志物研究的经验[J]. 化学进展, 2013, 25(09): 1454-1461.
[3] 黎钧耀. 癌症的营养干预研究[J]. 化学进展, 2013, 25(09): 1462-1479.
[4] Gary D. Stoner. 癌症预防的完全食物途径：以浆果为例[J]. 化学进展, 2013, 25(09): 1480-1491.
[5] 杨中枢. 维生素E和茶多酚用于癌症预防：动物模型和人群研究的体验[J]. 化学进展, 2013, 25(09): 1492-1500.
[6] 苏正元, 舒利民, Jong Hun Lee, Franciso Fuentes, 王虎, 吴天元, 余四旺, Ah-Ng Tony Kong. 食用植物成分和中药用于癌症化学预防：Nrf2,表观基因组学,癌症干细胞[J]. 化学进展, 2013, 25(09): 1526-1543.
[7] 王秀君*, 李欣, 唐修文. Nrf2通路在肿瘤化学预防中的研究进展[J]. 化学进展, 2013, 25(09): 1544-1552.
[8] 郜嵩, Sumit Basu, 杨广义, Arijita Deb, 胡明. 天然产物用于癌症化学预防的口服生物利用度问题[J]. 化学进展, 2013, 25(09): 1553-1574.
[9] 牛韬, 胡明. 微生物群结构、人类健康和癌症化学预防[J]. 化学进展, 2013, 25(09): 1601-1612.
阅读次数
全文


摘要

阿司匹林用于结直肠癌预防